Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 109,029

Document Document Title
WO/2015/107053A1
The present invention relates to compounds of the general formula I wherein Het is oxazole-5-yl, pyridin-4-yl, or pyrazol-4-yl; R1/ R2 are, independently from each other, hydrogen, lower alkyl, lower alkoxy, or halogen; W is -CH2- or -CH...  
WO/2015/106641A1
The present invention provides an anti-human proBDNF monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128th amino acid in a specific recognition pro-BDN...  
WO/2015/109037A1
The invention provides enantiopure deuterium- enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure d...  
WO/2015/107472A1
Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.  
WO/2015/105757A1
Provided is a method of treating or preventing a neurological disease or disorder (e.g., multiple sclerosis) in a subject in need thereof comprising orally administering to the subject a pharmaceutical composition comprising a therapeuti...  
WO/2015/104271A1
The present invention relates to compounds of formula (I) wherein Y is C-R1; R1 is hydrogen or halogen; R1 is hydrogen or halogen; R2 is hydrogen, lower alkyl or phenyl,; R4 is hydrogen or lower alkyl; or R2 and R4 may form together with...  
WO/2015/105772A1
The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of variou...  
WO/2015/105957A1
The presently disclosed subject matter relates to antagonists of PTEN and methods of using the same. In particular, the presently disclosed subject matter provides for PTEN antagonist peptides for use in treating central nervous system d...  
WO/2015/105201A1
The present invention provides a method of inducing microglia cells from blood cells, comprising culturing the blood cells in the presence of interleukin-34 (IL-34) and granulocyte-macrophage colony stimulating factor (GM-CSF).  
WO/2015/106032A1
The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related...  
WO/2015/103901A1
Disclosed is a stearoyl amino acid salt. The stearoyl amino acid salt has a structural formula represented by a general formula (I), R1 indicating H or an aromatic base capable of substituted by one or more substituents, or C1-4 straight...  
WO/2015/104443A1
The invention relates to the use of an isolated peptide, an antibody or a fusion protein that can bind to NPCT, and the compositions and pharmaceutical forms comprising same, in the development of a medicament for the treatment and/or pr...  
WO/2015/106098A1
The present invention provides fusion peptides, compositions, methods and kits for treating, reducing the risk of, lessening the severity of, preventing, or delaying the onset of amyloid-related disorders, such as Alzheimer's disease and...  
WO/2015/106066A1
The present invention provides cell-based assays, including high throughput cell-based assays, for identification of candidate therapeutic agents with the ability to inhibit microglial activation in vivo in response to different ligands.  
WO/2015/105929A1
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of va...  
WO/2015/106289A1
Disclosed herein are small-gap fullerene compositions and methods of using for therapeutic or cosmetic purposes. Specifically exemplified is the use of derivatized SGFs so as to be water-soluble. The derivatized SGFs include polyhydroxyl...  
WO/2015/102650A1
The present invention relates generally to prostatic acid phosphatase (PAP), compositions comprising the same, and methods for producing and/or purifying the same.  
WO/2015/100511A1
The invention concerns a method and the use of necrostatin-1 in the treatment of axonal degeneration caused by acute or chronic damage in diseases associated with Alzheimer's, Parkinson's, amyotrophic lateral sclerosis and multiple scler...  
WO/2015/102390A1
The present invention relates to: a novel amide derivative or a pharmaceutically acceptable salt thereof; a preparation method therefor; and a pharmaceutical composition for preventing or treating pain, containing the same. The novel ami...  
WO/2015/100512A1
The invention relates to a method and dose in the administration of drugs for the conscious sedation of a patient, for use in surgery, including, inter alia, endoscopic spine surgery, as well as other applications inside or outside the o...  
WO/2015/102419A1
Disclosed are a composition for inhibiting the N-end rule pathway, the composition containing a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof; a method for regulating the N-end rule pathway; and a method an...  
WO/2015/096551A1
An N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, a preparation method and an application. The structure of the compound is represented by formula (I). The compound can generate a rapid and rever...  
WO/2015/096187A1
Disclosed are a stable crystal I-form agomelatine tablet and a preparation method thereof. The preparation method thereof comprises the following steps: adding one or more protective agents into pure water, stirring, heating the mixture ...  
WO/2015/098991A1
The purpose of the present invention is to provide a novel compound, which strongly inhibits metabotropic glutamate receptor 5 signal transduction. The present invention provides the N-alkylamide derivative represented below or a pharmac...  
WO/2015/098857A1
Provided is a hydrated crystal of 4-(((6S,9S)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(qu inolone-8-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazi ne-6-yl)methyl)phenyl dihydrogen phosphate, said crystal having a diffraction pea...  
WO/2015/100353A1
Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimers disease. Also described are methods, systems and compositions to distinguish between Alzheimers disease and Park...  
WO/2015/099841A1
In one aspect, the present disclosure provides indazoles of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R3, R4, R5, R6, Z1, Z2, Z3, and G are defined as set forth in the specification. Further, ...  
WO/2015/095970A1
Covalent conjugates between lipoic acid (LA), or a derivative thereof, and edaravone, or a derivative thereof, are disclosed, including compounds of Formula I: (I) Therapeutic methods using the LA-edaravone conjugates are also described,...  
WO/2015/100217A1
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is g...  
WO/2015/097548A1
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R1a, R1b, R1c, X, Y, Z, G, O, W1 and W2 are defined as set forth in the specification. The invention is also ...  
WO/2015/097611A1
Disclosed are compositions comprising melatonin and astragaloside IV or astragalus extracts containing it.  
WO/2015/095968A1
Described are covalent conjugates between lipoic acid (LA), or a derivative thereof, and resveratrol, or a derivative thereof. As an example, the covalent conjugate may be a compound of the formula: (I). Methods using the LA-resveratrol ...  
WO/2015/095918A1
The invention relates to a method of treating or preventing pain, or a condition associated with pain, in a subject in need thereof, comprising applying topically an effective amount of an extract of Zingiber Officinale (ginger), and to ...  
WO/2015/097461A1
A compound of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, Wherein Q, R2, Ar, A and R1 are as defined in claim 1. The claimed compounds are gap junction blockers useful for the treatment or prevention of a range o...  
WO/2015/099167A1
Provided are: a vaccine against IL-17A, said vaccine using a polypeptide as an immunogen, and said polypeptide including the amino acid sequence shown in SEQ ID NO: 1 or including a non-human mammal derived amino acid sequence correspond...  
WO/2015/097463A1
The invention relates to pharmaceutically active compounds having improved pharmacokinetic properties and being useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain i...  
WO/2015/097545A1
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, Y, Z, and G are defined as set forth in the specification. The invention is also directed to use of compo...  
WO/2015/099196A1
The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, am...  
WO/2015/099094A1
 It is now understood that, from the preclinical stage of Alzheimer's disease, abnormalities in spine formation and the like occur due to worsening phosphorylation of MARCKS and the like, thereby leading to the onset of the disease in ...  
WO/2015/098591A1
1-(Benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is already known to exhibit an excellent activity/effect as an anti-depression drug, a psychotropic drug, an anti-Parkinson's disease d...  
WO/2015/095963A1
The invention provides isofogamine analogs of structural formula (I) below that modulate and stabilize glucocerebrosidases and enhance their enzymatic activity in vivo. Such compounds, prodrugs and compositions thereof are useful in trea...  
WO/2015/096651A1
Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses t...  
WO/2015/096771A1
Provided in the present invention are a compound having a structural feature of the general formula I as a novel retinoic acid orphan nuclear receptor γ subtype (RORγ) inhibitor, and the uses of the compound and a pharmaceutically acce...  
WO/2015/098441A1
Provided are a sleeping aid, a non-REM sleep time increasing agent, and a sedative with which a sense of deep sleep can be obtained. The sleeping aid, non-REM sleep time increasing agent, and sedative comprise an alpha-lipoic acid as an ...  
WO/2015/097546A1
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R'-R3 are defined as set forth in the specification. The invention is also directed to use of compounds of Formul...  
WO/2015/100252A1
Felbamate deuterated at the 2 position, compositions containing the same, and methods of making and using thereof are described herein. Substitution of the hydrogen at the 2 position with deuterium should prevent or reduce formation of t...  
WO/2015/096186A1
Disclosed are a stable crystal X-form agomelatine tablet and a preparation method thereof. The method comprises the following steps: selecting one or more protective agents, adding the protective agents into pure water, stirring, heating...  
WO/2015/096654A1
The present invention relates to the application of a specific inhibitor for an SHH signaling pathway. Disclosed for the first time are that the SHH signaling pathway and excitability of neural networks have a close relationship and are ...  
WO/2015/098963A1
Provided is a method for promoting the expression of calreticulin in at least one type of eukaryotic cell. Also provided is a synthetic peptide that can be used in said method. The method provided by the present invention includes prepar...  
WO/2015/099102A1
The purpose of the present invention is to provide a sleep-improving agent by which a feeling of deep sleep is obtained, a non-REM sleep time-increasing agent, and a sedative. The sleep-improving agent of the present invention contains z...  

Matches 551 - 600 out of 109,029